
A head-to-head comparison of ranibizumab (Lucentis, Genentech) and bevacizumab (Avastin, Genentech) in the Comparison of Age-related Macular Degeneration Treatments Trials indicated that at the 1-year time point, both drugs were clinically equivalent for treating the disease, said Daniel Martin, MD


.png)


